Introduction
============

Postoperative nausea and vomiting (PONV) is a common side effect after general anesthesia, with an incidence of around 30%.[@b1-dddt-9-2343] Risk factors for PONV are both anesthesia-related and non-anesthesia-related. Clinical studies show that the anesthesia-related risk factors for PONV are use of volatile anesthetics and postoperative opioid analgesics.[@b2-dddt-9-2343] However, the mechanism underlying these two primary risk factors is currently not well understood.[@b3-dddt-9-2343] Non-anesthesia-related risk factors for PONV include female sex, history of PONV or motion sickness, being a non-smoker, and younger age.[@b2-dddt-9-2343]

Although PONV is not a life-threatening medical complication, failure to control PONV substantially increases the time to discharge, resource utilization of the post-anesthesia care unit, and cost of medical care.[@b4-dddt-9-2343] Antiemetic drugs used to control PONV include cholinergic receptor antagonists, histamine receptor antagonists, serotonin antagonists, dopamine antagonists, and NK1 antagonists.[@b3-dddt-9-2343],[@b5-dddt-9-2343] Serotonin type 3 (5-HT3) receptor antagonists are the antiemetic drugs most commonly used in post-anesthesia care. The first line of choice among the 5-HT3 receptor antagonists is ondansetron.[@b6-dddt-9-2343] However, recent cardiac safety concerns regarding ondansetron limit its use in certain anesthesia settings if a high dose is required.[@b7-dddt-9-2343] Ramosetron is a newly developed 5-HT3 receptor antagonist which shows more prolonged activity than ondansetron and is very effective in preventing PONV.[@b8-dddt-9-2343]--[@b11-dddt-9-2343] To provide an updated evaluation of the effectiveness of ramosetron, we performed a meta-analysis on the efficacy and safety of ramosetron versus ondansetron using the most recently published randomized controlled clinical studies.

Materials and methods
=====================

Search strategy, selection criteria, and study quality assessment
-----------------------------------------------------------------

We searched the PubMed and EMBASE databases up to November 2014 for relevant clinical studies. Search terms used for PubMed were: ("ramosetron" \[Supplementary Concept\] OR "ramosetron" \[All Fields\]) AND ("ondansetron" \[MeSH Terms\] OR "ondansetron" \[All Fields\]) AND ("postoperative nausea and vomiting" \[MeSH Terms\] OR ("postoperative" \[All Fields\] AND "nausea" \[All Fields\] AND "vomiting" \[All Fields\]) OR "postoperative nausea and vomiting" \[All Fields\] OR "ponv" \[All Fields\]). Search terms used for EMBASE were: postoperative vomiting/or postoperative complication/or ondansetron/or ramosetron/or nausea/or vomiting/AND randomized clinical trial ramosetron.ti,ab./AND \*ondansetron/and \*ramosetron/. Clinical studies in the reference lists of recent published trials with retrievable full text were also searched. Randomized controlled clinical trials comparing the efficacy and safety profiles of ramosetron and ondansetron were selected by title and abstract screening followed by full text retrieval. Reviews, conference abstracts, and non-English language articles were excluded. Only studies using standard doses of ramosetron (4 mg) and ondansetron (0.3 mg) without dexamethasone as an adjunct were selected for meta-analysis. Two authors (CG, BL) independently performed the search and selected the relevant studies. Any discrepancy in the final selection was resolved by group discussion between all authors. The quality of the selected studies was assessed using the Jadad scoring system, which evaluates the randomization strategy, controls included, and description of withdrawal and dropouts in the study period. A study with a Jadad score ≥3 is regarded as being of high quality.[@b12-dddt-9-2343]

Data extraction, outcomes, and statistical analysis
---------------------------------------------------

Data extracted from each selected study were: author, year of publication, study design, number of patients analyzed, type of anesthesia, type of surgery, treatment regimen for ramosetron and ondansetron, and primary and secondary outcomes. The primary outcome was the incidence of postoperative nausea (PON) and postoperative vomiting (POV). The secondary outcome was side effects following administration of ramosetron or ondansetron, including headache, dizziness, and drowsiness. The meta-analysis was performed using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK). Dichotomous outcomes are presented as the relative risk (RR) with a 95% confidence interval (CI). The presence of heterogeneity was evaluated with the *I* [@b2-dddt-9-2343] statistic. *P*\<0.05 was considered to be statistically significant and a random-effects model was used for the meta-analysis. Fixed-effects model was used if heterogeneity was not significant across selected studies.

Results
=======

Study identification and characteristics
----------------------------------------

We identified a total of 68 records using our search strategy. Studies published by Yoshitaka Fujii were excluded due to concerns raised by other investigators.[@b10-dddt-9-2343],[@b11-dddt-9-2343] After initial title and abstract screening and full text retrieval, only nine studies met our selection criteria and were eligible for meta-analysis[@b13-dddt-9-2343]--[@b21-dddt-9-2343] ([Figure 1](#f1-dddt-9-2343){ref-type="fig"}). The characteristics of the selected studies are summarized in [Table 1](#t1-dddt-9-2343){ref-type="table"}. Most of these studies were very well designed randomized controlled clinical trials, with a Jadad score of 4 or 5.

Outcomes
--------

### Primary outcomes: PON and POV

A total of 898 patients from nine selected studies were treated with antiemetics after surgery, including 450 patients who received ondansetron 4 mg and 448 patients who received ramosetron 0.3 mg. PON and POV events were recorded at different time intervals in the nine studies. Meta-analysis of results showed no statistically significant difference in PON between patients receiving ramosetron and those receiving ondansetron in the different time periods in the 24 hours after surgery: 0--2 hours (RR 0.54, 95% CI 0.23--1.25; *P*=0.15), 0--6 hours (RR 0.84, 95% CI 0.44--1.63; *P*=0.61), 0--24 hours (RR 0.89, 95% CI 0.63--1.27; *P*=0.53), 2--24 hours (RR 0.47, 95% CI 0.15--1.49; *P*=0.2), or 6--24 hours (RR 0.88, 95% CI 0.58--1.35; *P*=0.56). However, ramosetron had a tendency to be more effective than ondansetron during the 24--48-hour time period after surgery, but this effect did not reach statistical significance (RR 0.60, 95% CI 0.36--1.01; *P*=0.06), ([Figure 2](#f2-dddt-9-2343){ref-type="fig"}). Ramosetron had different effects versus ondansetron on POV as compared with PON. During some of the time periods in the 24 hours after surgery, ramosetron showed higher efficacy than ondansetron for POV: 0--6 hours (RR 0.46, 95% CI 0.24--0.92; *P*=0.03), 0--24 hours (RR 0.72, 95% CI 0.52--1.00; *P*=0.05) and 6--24 hours (RR 0.51, 95% CI 0.31--0.84; *P*=0.008). At other time periods, including the 24--48 hours after surgery, ramosetron was no more effective than ondansetron in prevention of POV: 0--2 hours (RR 0.67, 95% CI 0.11--4.00; *P*=0.66), 2--6 hours (RR 0.55, 95% CI 0.21--1.47; *P*=0.24), 2--24 hours (RR 0.37, 95% CI 0.10--1.35; *P*=0.13), and 24--48 hours (RR 0.51, 95% CI 0.17--1.51; *P*=0.22, [Figure 3](#f3-dddt-9-2343){ref-type="fig"}). We did not include the study by Banerjee et al[@b22-dddt-9-2343] in our meta-analysis because these authors did not provide detailed PON and POV outcomes. However, their results showed that preoperative administration of a single intravenous dose of ramosetron 0.3 mg was more effective than a single intravenous dose of ondansetron 4 mg in reducing the incidence of PONV in general in the 18 hours after surgery.

### Secondary outcome: side effects of ramosetron and ondansetron

Four studies presented full data on side effects (headache, dizziness, drowsiness) after treatment with ramosetron or ondansetron in the 48 hours after surgery.[@b13-dddt-9-2343],[@b15-dddt-9-2343],[@b17-dddt-9-2343],[@b21-dddt-9-2343] Ramosetron had fewer recorded side effects than ondansetron (RR 0.65, 95% CI 0.47--0.91; *P*=0.01, [Figure 4](#f4-dddt-9-2343){ref-type="fig"}). Other studies did not present detailed data on side effects, but mentioned in their results that there was no statistically significant difference between ramosetron and ondansetron.

Publication bias
----------------

The potential publication bias of the selected studies was assessed using a Begg's funnel plot. No publication bias was detected for the time periods of 0--24 hours, 6--24 hours, and 24--48 hours. There was some publication bias concerning data for other time periods after surgery ([Figure 5](#f5-dddt-9-2343){ref-type="fig"}).

Discussion
==========

The previous positive clinical results published by Fujii et al on the efficacy of ramosetron have been criticized and reevaluated.[@b10-dddt-9-2343],[@b11-dddt-9-2343] The most recent meta-analysis by Mihara et al showed no significant difference between ramosetron and ondansetron in the prevention of PON.[@b10-dddt-9-2343] They found ramosetron was much more effective in the prevention of POV than ondansetron. Consistent with their results for PON, our meta-analysis showed no statistically significant difference between ramosetron and ondansetron in the prevention of PON during any of the time periods in the 48 hours after surgery, although ramosetron had a tendency to be more effective than ondansetron in the 24--48 hours after treatment. During some of the time periods in the 24 hours after surgery, we found a statistically significant difference between ramosetron and ondansetron with regard to prevention of POV (0--6 hours, 0--24 hours, and 6--24 hours). However, we did not find any difference between these two treatments in the 24--48-hour interval after surgery. To explore the cause for the inconsistency between our results and those of Mihara et al with regard to the ability of ramosetron to prevent late POV (24--48 hours), we compared the selected studies and the data extracted for late POV between our meta-analysis and that by Mihara et al. We included two new studies in our analysis[@b13-dddt-9-2343],[@b17-dddt-9-2343] and excluded a study by Choi et al[@b23-dddt-9-2343] that had been selected by Mihara et al. The study reported by Choi et al used dexamethasone as an adjunct to ramosetron and ondansetron for the treatment of PONV. Given that all other selected studies used only ramosetron or ondansetron, it was inappropriate to include a study with a different regimen. We also found a data extraction error in the meta-analysis by Mihara et al ie, in one selected study,[@b16-dddt-9-2343] late POV events in the ondansetron group were actually fewer than in the ramosetron group, according to line graph in the original study; however, in the publication by Mihara et al POV events in the ondansetron group were reported to be more common than in the ramosetron group (17 versus nine, respectively).

When comparing the total number of side effects including headache, dizziness, and drowsiness, ramosetron caused fewer recorded side effects than ondansetron in the 48 hours after surgery. In view of the US Food and Drug Administration warnings regarding the use of ondansetron in patients with a prolonged QT interval,[@b24-dddt-9-2343] improved safety would be a good reason to replace ondansetron with ramosetron, even though there was no significant difference in efficacy between these two treatments.

Our meta-analysis has some limitations. The total number of patients analyzed was only 898, with PON and POV events recorded at different time periods in the different studies, so the sample size for each time period was very small. Further, ramosetron is only licensed in Asian countries, with the selected studies all being conducted in Asian population, and it is unclear whether our conclusion is applicable to other populations. Finally, we detected some publication bias in the data on PON and POV events during some time periods in the 24 hours following surgery. Therefore, results for those time periods may not be accurate.

In summary, our current meta-analysis demonstrates that ramosetron was much more effective than ondansetron in the prevention of early POV (0--24 hours) and was associated with fewer side effects. However, our study did not identify any statistically significant differences in efficacy between ramosetron and ondansetron in the prevention of PON and late POV (24--48 hours).
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![Forest plot of relative risk comparing postoperative nausea between ramosetron and ondansetron treatment.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel test.](dddt-9-2343Fig2){#f2-dddt-9-2343}

![Forest plot of relative risk comparing postoperative vomiting between ramosetron and ondansetron treatment.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel test.](dddt-9-2343Fig3){#f3-dddt-9-2343}

![Forest plot of relative risk comparing side effects between ramosetron and ondansetron treatment.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel test.](dddt-9-2343Fig4){#f4-dddt-9-2343}

![Funnel plot for the assessment of publication bias.\
**Abbreviations:** RR, relative risk; SE, standard error.](dddt-9-2343Fig5){#f5-dddt-9-2343}

###### 

Study characteristics

  Reference                        Study design   Type of anesthesia                                     Type of surgery                Treatment regimen                                                                            Outcomes                                                                     Patients analyzed (n)   Jadad score
  -------------------------------- -------------- ------------------------------------------------------ ------------------------------ -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------- -------------
  Ryu et al[@b13-dddt-9-2343]      RCT, DB        Propofol 4 μg/mL + remifentanil 3--4 ng/mL             Craniotomy                     Ondansetron 4 mg (group A), ondansetron 8 mg (group B), or ramosetron 0.3 mg (group C); IV   PONV (0--48 hours); drowsiness, dizziness, and QTc prolongation              127                     5
  Kaja et al[@b14-dddt-9-2343]     RCT            Propofol 2 mg/kg + fentanyl 2 μg/kg + N~2~O            Abdominal surgery              Ramosetron 0.3 mg; ondansetron 4 mg; IV                                                      PONV (0--24 hours); headache, dizziness, drowsiness, EPS                     60                      3
  Lee et al[@b15-dddt-9-2343]      RCT, DB        1.0--4.0 vol% sevoflurane and 50% N~2~O in oxygen      Abdominal hysterectomy         Ramosetron 0.3 mg; ondansetron 4 mg; IV                                                      PONV (0--48 hours); headache, dizziness                                      120                     4
  Choi et al[@b16-dddt-9-2343]     RCT, DB        Propofol and remifentanil                              Cardiac surgery                Ramosetron 0.3 mg +0.6 mg in PCA; ondansetron 4 mg +12 mg in PCA; IV                         PONV (0--48 hours); headache, dizziness, diarrhea, episodes of arrhythmias   279                     5
  Ansari et al[@b17-dddt-9-2343]   RCT, DB        Sevoflurane + N~2~O                                    Laparoscopic cholecystectomy   Ramosetron 0.3 mg; ondansetron 4 mg; IV                                                      PONV (0--48 hours); headache, dizziness, dyspepsia, weakness, flushing       130 (female)            5
  Hahm et al[@b18-dddt-9-2343]     RCT, DB        Propofol 0.5--2.0 μg/mL                                Total knee replacement         Ramosetron 0.3 mg; ondansetron 4 mg; IV                                                      PONV (0--48 hours)                                                           84 (female)             4
  Ryu et al[@b19-dddt-9-2343]      RCT, DB        Desflurane 3%--6% + remifentanil 2--3 ng/mL            Laparoscopic cholecystectomy   Ramosetron 0.3 mg; ondansetron 4 or 8 mg; IV                                                 PONV (0--48 hours); headache, dizziness, drowsiness                          120                     5
  Kim et al[@b20-dddt-9-2343]      RCT, DB        Sevoflurane 0.5%--5% + N~2~O                           Gynecological surgery          Ramosetron 0.3 mg; ondansetron 8 mg; IV                                                      PONV (0--24 hours); headache, dizziness                                      162                     5
  Choi et al[@b21-dddt-9-2343]     RCT, DB        Propofol 1.5--2.5 mg/kg and remifentanil 0.5--1 g/kg   Lumbar spine surgery           Ramosetron 0.3 mg; ondansetron 4 mg +12 mg in PCA; IV                                        PONV (0--48 hours); headache, dizziness, drowsiness                          94 (female)             5

**Abbreviations:** RCT, randomized controlled trial; DB, double-blind; PONV, postoperative nausea and vomiting; EPS, extrapyramidal symptoms; IV, intravenously; PCA, patient-controlled analgesia.
